<?xml version="1.0" encoding="UTF-8"?>
<abstract id="15708844">
  <title>
    <s id="0" section="title">
      Acute treatment of moderate to severe depression with
      <group id="0">
        <short>hypericum</short>
        extract  WS  5570  (  <short>St  John's  wort</short>  )
      </group>
      : randomised controlled double blind non - inferiority trial versus
      <group id="1">paroxetine</group>
      .
    </s>
  </title>
  <annotated>
    <s id="1" section="objective">
      To investigate the efficacy of
      <group id="0">
        <short>hypericum</short>
        extract  WS  5570  (  <short>St John's  wort</short>  )
      </group>
      compared with
      <group id="1">paroxetine</group>
      in patients with moderate to severe major depression .
    </s>
    <s id="3" section="setting">21 psychiatric primary care practices in Germany .</s>
    <s id="4" section="participants">
      <ps>251</ps>
      adult outpatients with acute major depression with total score &gt; or = 22 on the 17 item Hamilton depression scale .
    </s>
    <s id="5" section="interventions">
      <group id="0">
        900  mg  /  day
        <short>hypericum</short>
        extract  WS  5570  3  times  a  day
      </group>
      or
      <group id="1">
        20  mg
        <short>paroxetine</short>
        once  a  day
      </group>
      for
      <time id="0">6  weeks</time>
      .
    </s>
    <s id="6" section="interventions">
      In initial non - responders doses were increased to
      <group id="0">
        1800  mg  /  day
        <short>hypericum</short>
      </group>
      or
      <group id="1">
        40  mg  /  day
        <short>paroxetine</short>
      </group>
      after
      <time id="2">2  weeks</time>
      .
    </s>
    <s id="7" section="main_outcome_measures">
      Change in score on
      <outcome id="0">
        <short>Hamilton  depression  scale</short>
        from
        <time id="1">baseline</time>
        to
        <time id="0">day  42</time>
      </outcome>
      ( primary outcome ) .
    </s>
    <s id="10" section="results">
      The intention to treat analysis ( lower 1 sided 97.5 % confidence limit 1.5 points for the difference
      <group id="0">hypericum</group>
      minus
      <group id="1">paroxetine</group>
      ) and the per protocol analysis ( lower confidence limit 0.7 points ) showed non - inferiority of
      <group id="0">hypericum</group>
      and statistical superiority over
      <group id="1">paroxetine</group>
      .
    </s>
    <s id="11" section="results">
      The lower limits in both cases exceeded the pre - specified non - inferiority margin of - 2.5 points and the superiority margin of 0 . The
      <outcome id="4">
        incidence  of
        <short>adverse  events</short>
      </outcome>
      was 0.035 and 0.060 events per day of exposure for
      <group id="0">hypericum</group>
      and
      <group id="1">paroxetine</group>
      , respectively .
    </s>
    <s id="12" section="conclusions">
      In the treatment of moderate to severe major depression ,
      <group id="0">
        <short>hypericum</short>
        extract  WS  5570
      </group>
      is at least as effective as
      <group id="1">paroxetine</group>
      and is better tolerated .
    </s>
  </annotated>
  <fulltext>Acute treatment of moderate to severe depression with hypericum extract WS 5570 ( St John 's wort ) : randomised controlled double blind non - inferiority trial versus paroxetine . To investigate the efficacy of hypericum extract WS 5570 ( St John 's wort ) compared with paroxetine in patients with moderate to severe major depression . Randomised double blind , double dummy , reference controlled , multicentre non - inferiority trial . 21 psychiatric primary care practices in Germany . 251 adult outpatients with acute major depression with total score &gt; or = 22 on the 17 item Hamilton depression scale . 900 mg / day hypericum extract WS 5570 3 times a day or 20 mg paroxetine once a day for 6 weeks . In initial non - responders doses were increased to 1800 mg / day hypericum or 40 mg / day paroxetine after 2 weeks . Change in score on Hamilton depression scale from baseline to day 42 ( primary outcome ) . Secondary measures were change in scores on Montgomery-Asberg depression rating scale , clinical global impressions , and Beck depression inventory . The Hamilton depression total score decreased by mean 14.4 ( SD 8.8 ) points , corresponding to 56.6 % ( SD 34.3 % ) of the baseline value , in the hypericum group and by 11.4 ( SD 8.6 ) points ( 44.8 % ( SD 33.5 % ) of baseline value ) in the paroxetine group ( intention to treat analysis ; similar results were observed in the per protocol analysis ) . The intention to treat analysis ( lower 1 sided 97.5 % confidence limit 1.5 points for the difference hypericum minus paroxetine ) and the per protocol analysis ( lower confidence limit 0.7 points ) showed non - inferiority of hypericum and statistical superiority over paroxetine . The lower limits in both cases exceeded the pre - specified non - inferiority margin of - 2.5 points and the superiority margin of 0 . The incidence of adverse events was 0.035 and 0.060 events per day of exposure for hypericum and paroxetine , respectively . In the treatment of moderate to severe major depression , hypericum extract WS 5570 is at least as effective as paroxetine and is better tolerated .</fulltext>
  <ignored>
    <s id="2" section="design">Randomised double blind , double dummy , reference controlled , multicentre non - inferiority trial .</s>
    <s id="8" section="main_outcome_measures">
      Secondary measures were change in scores on
      <outcome id="1">Montgomery-Asberg  depression  rating  scale</outcome>
      ,
      <outcome id="2">clinical  global  impressions</outcome>
      , and
      <outcome id="3">Beck  depression  inventory</outcome>
      .
    </s>
    <s id="9" section="results">
      The
      <outcome id="0">Hamilton  depression  total  score</outcome>
      decreased by mean 14.4 ( SD 8.8 ) points , corresponding to 56.6 % ( SD 34.3 % ) of the baseline value , in the
      <group id="0">hypericum  group</group>
      and by 11.4 ( SD 8.6 ) points ( 44.8 % ( SD 33.5 % ) of baseline value ) in the
      <group id="1">paroxetine  group</group>
      ( intention to treat analysis ; similar results were observed in the per protocol analysis ) .
    </s>
  </ignored>
</abstract>

